Stifel Financial Corp Has $91.70 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Stifel Financial Corp increased its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 6.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 404,135 shares of the medical instruments supplier's stock after acquiring an additional 25,987 shares during the period. Stifel Financial Corp owned approximately 0.14% of Becton, Dickinson and Company worth $91,701,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Becton, Dickinson and Company by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier's stock worth $6,067,196,000 after buying an additional 184,288 shares during the period. Geode Capital Management LLC raised its holdings in shares of Becton, Dickinson and Company by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier's stock valued at $1,437,161,000 after acquiring an additional 66,024 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of Becton, Dickinson and Company by 15.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock valued at $1,401,126,000 after acquiring an additional 810,345 shares in the last quarter. First Eagle Investment Management LLC boosted its stake in Becton, Dickinson and Company by 31.4% in the 4th quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock worth $1,004,132,000 after purchasing an additional 1,057,879 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Becton, Dickinson and Company by 6.7% in the fourth quarter. Invesco Ltd. now owns 4,265,638 shares of the medical instruments supplier's stock valued at $967,745,000 after purchasing an additional 267,436 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Jeffrey William Henderson bought 1,500 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were acquired at an average cost of $233.62 per share, with a total value of $350,430.00. Following the completion of the transaction, the director now directly owns 8,015 shares in the company, valued at $1,872,464.30. This represents a 23.02 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the transaction, the executive vice president now directly owns 4,887 shares of the company's stock, valued at approximately $964,107.36. This trade represents a 8.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,578 shares of company stock worth $795,986 over the last three months. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Performance

BDX traded up $0.85 on Friday, hitting $205.30. The company had a trading volume of 1,690,556 shares, compared to its average volume of 1,733,176. Becton, Dickinson and Company has a 1-year low of $193.03 and a 1-year high of $251.99. The stock has a market cap of $58.95 billion, a price-to-earnings ratio of 34.10, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The company's fifty day moving average price is $218.51 and its 200 day moving average price is $227.33.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its board has authorized a share buyback plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Monday, March 10th were issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.03%. The ex-dividend date was Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 69.10%.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Piper Sandler lowered their price target on Becton, Dickinson and Company from $280.00 to $260.00 and set an "overweight" rating on the stock in a report on Wednesday. StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, April 2nd. Finally, Barclays decreased their price target on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating for the company in a report on Monday, April 7th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of "Buy" and an average price target of $272.86.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.